MacNew
The MacNew Instrument is protected by national and international laws. The Berne Convention and the national laws on intellectual property fully apply to the MacNew Instrument and its documents.
MacNew.org as the copyright holder of the MacNew Instrument controls access (distribution and reproduction), its adaptation or modification, and its translation. Copyright is a means to protect the integrity of an instrument.
Get a license
Yes, there is the requirement to agree in writing to our standard conditions for using the MacNew as outlined in the licensing contract.
Yes, please get in touch with us: info@macnew.org.
The license fee can be paid online by credit/debit card (processed securely by our payment
service provider Wise Europe SA on their secure payment page – card details are never entered on this
website), by PayPal, or via bank transfer.
All fees are charged in euros (symbol: €, currency code: EUR). The licensed materials
are delivered electronically as digital documents; once delivered, the license fee is non-refundable. No export
restrictions apply. Details: Payment, Delivery & Refund Policy.
Yes, after receiving written permission from us you may make copies of the PDF MacNew for your specific project. This will be granted after [you/company name] accepts the license agreement.
The MacNew scoring algorithm allows missing items as long as >50% of the items are scored.
Yes, we will provide the licensees with an Excel Scoring Sheet as well as an SPSS syntax file.
The MacNew has been validated for patients with myocardial infarction, angina, heart failure, as well as in patients with a pacemaker. In addition, normative data are available for patients with myocardial infarction, angina, and heart failure. The MacNew is the core patient reported outcome instrument assessing all three aspects of health (according to the health definition of the WHO: physical, mental and social well-being) in coronary artery disease patients.
The MacNew questionnaire has a two-week time frame and has been applied at different time points after the event/diagnosis as well as in the acute phase and is sensitive to change in HRQL with moderate to large effect sizes.
The MacNew has been validated in all major ischemic heart disease diagnoses (myocardial infarction, angina, heart failure) as well as in patients with a pacemaker with demonstrated effectiveness in these conditions.